CRISPR/Cas9‐mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1‐mutated breast cancer cells

For patients carrying BRCA1 mutations, at least one‐third develop triple negative breast cancer (TNBC). Not only is TNBC difficult to treat due to the lack of molecular target receptors, but BRCA1 mutations (BRCA1m) also result in chemotherapeutic resistance, making disease recurrence more likely. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Mintz, Rachel L., Lao, Yeh‐Hsing, Chi, Chun‐Wei, He, Siyu, Li, Mingqiang, Quek, Chai Hoon, Shao, Dan, Chen, Boyuan, Han, Jing, Wang, Sihong, Leong, Kam W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971465/
https://www.ncbi.nlm.nih.gov/pubmed/31989039
http://dx.doi.org/10.1002/btm2.10152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971465/
https://www.ncbi.nlm.nih.gov/pubmed/31989039
http://dx.doi.org/10.1002/btm2.10152

Ejemplares similares